Remdesivir was one of many first medicines accredited for therapy of COVID-19. Scientific research evaluated its effectiveness, however didn’t generate conclusive outcomes. A brand new evaluation of the research information exhibits {that a} particular group of sufferers advantages probably the most from the drug.